Weight Loss Appetite Suppressant Injections: What They Actually Do

You've cut back on food and still feel hungry most of the day

That's an experience a large number of people describe before starting one of the licensed weight loss injections. The frustrating reality is that reducing calories triggers the body to increase hunger signals, it's a biological response, not a failure of resolve. This is where GLP-1 and GIP receptor agonists work differently from calorie restriction alone.

When you eat, your gut releases hormones including GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). These hormones tell the brain you've had enough, slow the rate at which your stomach empties, and influence how satisfied you feel after a meal. In people with obesity, these signals can be weaker or shorter-lived. Mounjaro mimics both GIP and GLP-1; Wegovy mimics GLP-1 alone. Both work by amplifying the body's own fullness signals rather than suppressing appetite through stimulants or central nervous system effects.

In practice, many people on these medicines report that portions naturally shrink, that the pull toward high-calorie foods feels less urgent, and that they can stop eating at a reasonable point without a conscious effort. The NHS patient information for tirzepatide explains this mechanism clearly, and there's more detail on how appetite suppression actually works if you want a deeper look. Worth knowing: the appetite change tends to be most noticeable in the first weeks at each dose and often continues, though the intensity can vary between people.

What the clinical trial results show, and how to read them honestly

Trial results for appetite suppressant injections are frequently quoted in headlines, sometimes without context. Here's what the evidence actually says.

SURMOUNT-1, published in the New England Journal of Medicine, followed thousands of adults with obesity over 72 weeks. At the highest dose of tirzepatide (15mg), participants lost an average of around 20–21% of body weight. STEP 1, the equivalent trial for semaglutide 2.4mg, reported an average reduction of around 15% over 68 weeks. Both trials involved reduced-calorie eating and increased physical activity alongside the medicine, the injections are licensed as an addition to lifestyle changes, not a replacement for them.

These are group averages. Individual results vary, and the prescriber's job at follow-up is to check that you're responding adequately. NICE guidance on tirzepatide, TA1026, notes that continuing treatment is reviewed if weight loss is under 5% after six months at the highest tolerated dose. That's a genuine safety checkpoint, not a bureaucratic hurdle.

If you're curious how Mounjaro and Wegovy compare head to head, the overview of weight loss injections on this site walks through the SURMOUNT-5 evidence in plain language. Both medicines are also the subject of ongoing post-approval monitoring, Mounjaro and Wegovy each carry the Black Triangle (▼) designation, meaning the MHRA collects additional safety data from real-world use.

Who these injections are licensed for, and what a clinical assessment actually checks

The licensed eligibility threshold for both medicines as private prescriptions is adults with a BMI of 30 or above, or 27 or above if you have at least one weight-related health condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. That said, BMI alone doesn't decide suitability. A prescriber also looks at your medical history, current medications, and any conditions that would make these medicines unsuitable, a personal clinical review, not an automated threshold check.

Before a prescription can be issued, UK regulations require photo ID verification and weight confirmation. At nume, weight is confirmed on a live video call by a GPhC-registered Independent Prescriber, a real clinician reviews your consultation the same day, not software routing answers through a decision tree. You can read about our clinical approach if you'd like to know more about how that process is run.

There are situations where these medicines are not suitable: pregnancy, breastfeeding, and actively trying to conceive all mean these treatments aren't recommended. They're also not licensed for anyone under 18. Certain conditions (a history of pancreatitis, some thyroid cancers, specific gastrointestinal disorders) require careful prescriber discussion. Some common medications interact with these treatments too; for instance, there are specific considerations for women on the oral contraceptive pill alongside tirzepatide. The page on taking weight loss injections with other medicines covers a range of these interactions in more depth.

Side effects to be aware of before you start

The most common side effects of both Mounjaro and Wegovy are gastrointestinal: nausea, loose stools, constipation, indigestion, burping, and sometimes vomiting. These are a direct consequence of how the medicines work, slowing gastric emptying means food sits in the stomach longer, which can feel uncomfortable, particularly in the first days after starting or after a dose increase. For most people, these effects settle within a week or two as the body adjusts.

A useful habit: before your first injection, read the Patient Information Leaflet that comes in the box. It takes about five minutes and lists not just common side effects but the rarer ones that need prompt medical attention, including symptoms of pancreatitis (severe stomach pain that spreads to the back, with or without vomiting) and signs of an allergic reaction. The MHRA highlighted acute pancreatitis as a known risk in a Drug Safety Update in January 2026, and knowing the symptom pattern means you'd recognise it quickly if it occurred. Suspected side effects can be reported at the MHRA Yellow Card service.

Injection-site reactions (mild redness or firmness at the site) are also possible. Rotating sites between the abdomen, thigh, and upper arm each week reduces the chance of this building up. If you're new to self-injection, our prescribers are available seven days a week for aftercare questions, and our guide to how a weight loss injection works in practice is a good place to get your bearings before you start. There's a transparent summary of what's included in the cost of treatment if you'd like to understand what that aftercare access looks like in practice.

When you're ready, a free consultation with our prescribers is the right next step. There's no obligation, and it's the only way to find out whether one of these treatments is clinically appropriate for you. If you're weighing up how much of the effect comes down to appetite alone, the page on whether weight loss injections do more than just suppress appetite sets out the fuller picture. Start your free consultation.